MCID: HYP006
MIFTS: 50

Hypertensive Heart Disease malady

Categories: Cardiovascular diseases

Aliases & Classifications for Hypertensive Heart Disease

Summaries for Hypertensive Heart Disease

Disease Ontology : 12 A heart disease that is caused by high blood pressure.

MalaCards based summary : Hypertensive Heart Disease is related to myocardial infarction and heart disease. An important gene associated with Hypertensive Heart Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Pathways in cancer and Colorectal Cancer Metastasis. The drugs Irbesartan and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include heart, monocytes and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 71 Hypertensive heart disease includes a number of complications of high blood pressure that affect the... more...

Related Diseases for Hypertensive Heart Disease

Diseases related to Hypertensive Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 28.0 ACE AGT AGTR1 CTF1 MMP2 MMP9
2 heart disease 10.8
3 cardiomyopathy 10.3
4 penile cancer, childhood 10.3 ACE AGT
5 inferolateral myocardial infarct 10.2 ACE NPPB
6 iris disease 10.2 ACE AGT AGTR1
7 preaxial polydactyly of fingers 10.2 ACE AGT AGTR1
8 cascade stomach 10.2 ACE AGT AGTR1
9 hyperuricemic nephropathy, familial juvenile 2 10.2 ACE AGT AGTR1
10 cetp-related hyperalphalipoproteinemia 10.2 ACE AGT AGTR1
11 flat umbilicus familial 10.2 ACE AGT AGTR1
12 agammaglobulinemia 6 10.2 ACE AGT AGTR1
13 joint disorders 10.2 ACE AGTR1 NPPB
14 petrositis 10.2 ACE AGTR1 NPPB
15 hypogonadism mitral valve prolapse mental retardation 10.2 ACE CYP11B2
16 lymphadenitis 10.2 ACE AGTR1 NPPB
17 systolic heart failure 10.2 ACE AGT AGTR1
18 familial nephrotic syndrome 10.2 ACE AGT AGTR1
19 intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.1 AGTR1 CYP11B2
20 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.1 ACE AGT NPPB
21 adams-oliver syndrome 10.1 ACE AGT NPPB
22 hypertrichosis of eyelid 10.1 ACE AGTR1 NR3C2
23 hemorrhagic cystitis 10.1 AGTR1 CD36 NR3C2
24 mental retardation hypocupremia hypobetalipoproteinemia 10.1 AGT AGTR1
25 iida kannari syndrome 10.1 ACE NPPB NR3C2
26 leber congenital amaurosis 10.1 CD36 MMP1
27 polyp of corpus uteri 10.1 MMP1 MMP2
28 angiomyoma 10.1 MMP1 MMP2
29 eastern equine encephalitis 10.1 ACE AGT AGTR1 NPPB
30 hypoaldosteronism, congenital, due to cmo i deficiency 10.0 AGT CYP11B2 NR3C2
31 panuveitis 10.0 AGTR1 CYP11B2 NR3C2
32 speech and communication disorders 10.0 CD36 MMP2
33 adult-onset distal myopathy due to vcp mutation 10.0 MMP1 MMP9
34 diffuse large b-cell lymphoma 10.0 MMP1 MMP9
35 noonan syndrome 4 10.0 CD36 MMP1 MMP2
36 microphthalmia, isolated, with coloboma 7 10.0 ACE CYP11B2 NR3C2
37 prostate neuroendocrine neoplasm 10.0 ACE AGT AGTR1 NR3C2
38 zika fever 10.0 CD36 MMP1 MMP2
39 ectropion 10.0 MMP1 MMP9
40 cystic lymphangioma 10.0 MMP1 MMP9
41 aplasia cutis congenita recessive 10.0 ACE AGT AGTR1 CYP11B2
42 syringomelia hyperkeratosis 10.0 ACE NPPB
43 facio skeletal genital syndrome rippberger type 10.0 MMP2 MMP9
44 xanthogranulomatous pyelonephritis 10.0 ACE AGTR1 NPPB NR3C2
45 acute tricyclic antidepressant poisoning 10.0 MMP2 MMP9
46 ischemia 10.0
47 leukoencephalopathy palmoplantar keratoderma 9.9 MMP2 MMP9
48 familial nasal acilia 9.9 AGT AGTR1 CYP11B2 NR3C2
49 cervix small cell carcinoma 9.9 ACE AGTR1 MMP9
50 thymus adenocarcinoma 9.9 MMP2 MMP9

Comorbidity relations with Hypertensive Heart Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypertensive Heart Disease:



Diseases related to Hypertensive Heart Disease

Symptoms & Phenotypes for Hypertensive Heart Disease

MGI Mouse Phenotypes related to Hypertensive Heart Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE AGT AGTR1 CD36 CYP11B2 MMP2
2 growth/size/body region MP:0005378 9.97 MMP2 MMP9 NR3C2 ACE AGT AGTR1
3 homeostasis/metabolism MP:0005376 9.96 AGT AGTR1 CD36 CTF1 CYP11B2 MMP1
4 adipose tissue MP:0005375 9.88 ACE AGT AGTR1 CD36 CTF1 CYP11B2
5 immune system MP:0005387 9.76 ACE AGT AGTR1 CD36 CYP11B2 MMP1
6 nervous system MP:0003631 9.56 AGT AGTR1 CD36 CTF1 CYP11B2 MMP2
7 renal/urinary system MP:0005367 9.17 ACE AGT AGTR1 CD36 CYP11B2 MMP9

Drugs & Therapeutics for Hypertensive Heart Disease

Drugs for Hypertensive Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3 138402-11-6 3749
2
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
3
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
4
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
5
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
6
Spironolactone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1952-01-7, 52-01-7 5833
7
Amiloride Approved Phase 4,Phase 2,Phase 3 2016-88-8, 2609-46-3 16231
8
Amlodipine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 88150-42-9 2162
9
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
10
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
11
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
12
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
13
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
14
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
15
Benazepril Approved, Investigational Phase 4,Phase 3 86541-75-5 5362124
16
Eprosartan Approved Phase 4 133040-01-4 5281037
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
18
Fosinopril Approved Phase 4 98048-97-6 55891
19
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83915-83-7 5362119
20
Losartan Approved Phase 4,Phase 3,Phase 2,Early Phase 1 114798-26-4 3961
21
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
22
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
23
Perindopril Approved Phase 4,Phase 2 107133-36-8, 82834-16-0 107807
24
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
27
Trandolapril Approved Phase 4 87679-37-6 5484727
28
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
29
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
30
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-93-5 3639
31
Nifedipine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 21829-25-4 4485
32
Ticlopidine Approved Phase 4,Phase 2,Phase 3 55142-85-3 5472
33
Menthol Approved Phase 4,Phase 2,Phase 3 2216-51-5 16666
34
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-78-2 2244
35
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
36
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
37
Nebivolol Approved, Investigational Phase 4,Phase 3 152520-56-4, 99200-09-6, 118457-14-0 71301
38
Allopurinol Approved Phase 4 315-30-0 2094
39
Indapamide Approved Phase 4 26807-65-8 3702
40
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
41
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
42
Mechlorethamine Approved Phase 4 51-75-2 4033
43
Captopril Approved Phase 4,Early Phase 1 62571-86-2 44093
44
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
45
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
46
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
47
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
48 Benidipine Approved Phase 4 105979-17-7
49 Lacidipine Approved Phase 4 103890-78-4
50
Felodipine Approved, Investigational Phase 4,Phase 3 72509-76-3 3333

Interventional clinical trials:

(show top 50) (show all 471)
id Name Status NCT ID Phase
1 Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan Unknown status NCT00517322 Phase 4
2 Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human Unknown status NCT01069042 Phase 4
3 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4
4 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4
5 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4
6 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4
7 Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Unknown status NCT01394770 Phase 4
8 Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients Unknown status NCT01048047 Phase 4
9 The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population Unknown status NCT00966199 Phase 4
10 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4
11 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4
12 Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics Unknown status NCT01715584 Phase 4
13 ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia Unknown status NCT01415284 Phase 4
14 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4
15 Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease Completed NCT01203696 Phase 4
16 To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure. Completed NCT00170924 Phase 4
17 The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis Completed NCT00852514 Phase 4
18 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4
19 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4
20 The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease Completed NCT00673075 Phase 4
21 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4
22 I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT00362037 Phase 4
23 Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients Completed NCT01284114 Phase 4
24 Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF Completed NCT01435161 Phase 4
25 Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy Completed NCT01425411 Phase 4
26 ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling Completed NCT01176032 Phase 4
27 Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart Completed NCT01961323 Phase 4
28 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Completed NCT00753012 Phase 4
29 Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. Completed NCT00409942 Phase 4
30 Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) Completed NCT00294567 Phase 4
31 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Completed NCT00307463 Phase 4
32 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed NCT00129233 Phase 4
33 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4
34 Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) Completed NCT00454662 Phase 4
35 Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension Completed NCT00672113 Phase 4
36 Eplerenone in Systemic Right Ventricle Completed NCT00703352 Phase 4
37 Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension Completed NCT00139555 Phase 4
38 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4
39 Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients Completed NCT00974857 Phase 4
40 Simvastatin and Diastolic Dysfunction Completed NCT01061450 Phase 4
41 Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension Completed NCT02426099 Phase 4
42 Smoking Study With Behavioral Therapy for Hypertensive Patients Completed NCT00879177 Phase 4
43 Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients Completed NCT01508325 Phase 4
44 Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients Completed NCT02144922 Phase 4
45 Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve Completed NCT01490398 Phase 4
46 Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study Completed NCT00408512 Phase 4
47 Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes Completed NCT00123604 Phase 4
48 Valsartan Intensified Primary Care Reduction of Blood Pressure Study Completed NCT00902304 Phase 4
49 Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus Completed NCT00136773 Phase 4
50 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4

Search NIH Clinical Center for Hypertensive Heart Disease

Genetic Tests for Hypertensive Heart Disease

Anatomical Context for Hypertensive Heart Disease

MalaCards organs/tissues related to Hypertensive Heart Disease:

39
Heart, Monocytes, Endothelial, Bone, Kidney, Bone Marrow, Tongue

Publications for Hypertensive Heart Disease

Articles related to Hypertensive Heart Disease:

(show top 50) (show all 365)
id Title Authors Year
1
MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. ( 28531963 )
2017
2
Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. ( 27571318 )
2016
3
Case 2/2016 - 76-Year-Old Male with Hypertensive Heart Disease, Renal Tumor and Shock. ( 27305288 )
2016
4
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27753836 )
2016
5
Shape analysis of hypertrophic and hypertensive heart disease using MRI-based 3D surface models of left ventricular geometry. ( 26766206 )
2016
6
Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness a8Y 15 mm. ( 27368925 )
2016
7
Electrocardiography for Assessment of Hypertensive Heart Disease: A New Role for an Old Tool. ( 27160048 )
2016
8
Obesity and hypertensive heart disease: focus on body composition and sex differences. ( 27956942 )
2016
9
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. ( 27797437 )
2016
10
Fragmented QRS complexes are a marker of myocardial fibrosis in hypertensive heart disease. ( 27774963 )
2016
11
Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. ( 27260191 )
2016
12
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27642917 )
2016
13
The interplay between renin-angiotensin system activation, abnormal myocardial deformation and neurohumoral activation in hypertensive heart disease: a speckle tracking echocardiography study. ( 27787699 )
2016
14
Recurrent Syncope: An Unusual Complication of Hypertensive Heart Disease. ( 27448490 )
2016
15
SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH. ( 27642889 )
2016
16
Prognostic Implications of LV Strain RiskA ScoreA inA Asymptomatic Patients WithA Hypertensive Heart Disease. ( 27344417 )
2016
17
The septal bulge-an early echocardiographic sign in hypertensive heart disease. ( 26850524 )
2016
18
JS ISH-ESH-2 UPDATE ON THE DETECTION AND FOLLOW-UP OF EARLY HYPERTENSIVE HEART DISEASE. ( 27754006 )
2016
19
Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. ( 27142065 )
2016
20
The Relationship Between Left Ventricular Wall Thickness, Myocardial Shortening, and Ejection Fraction in Hypertensive Heart Disease: Insights From Cardiac Magnetic Resonance Imaging. ( 27316563 )
2016
21
Effect of Renal Sympathetic Denervation on Specific MicroRNAs as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease. ( 26916982 )
2016
22
Aircraft, road and railway traffic noise as risk factors for heart failure and hypertensive heart disease-A case-control study based on secondary data. ( 27667192 )
2016
23
T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. ( 26659373 )
2015
24
Safety of digoxin use in patients with hypertensive heart disease and atrial fibrillation. ( 26039531 )
2015
25
Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. ( 26443037 )
2015
26
Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease. ( 26577946 )
2015
27
Myocardial dysfunction in patients with aortic stenosis and hypertensive heart disease assessed by MR tissue phase mapping. ( 26687082 )
2015
28
Hypertensive heart disease and bronchodilators: Potential left ventricular outflow obstruction. ( 26093159 )
2015
29
Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. ( 26705488 )
2015
30
CMR imaging of extracellular volume and myocardial strain in hypertensive heart disease. ( 25677890 )
2015
31
Hypertensive heart disease in paced-hearts. ( 26522996 )
2015
32
Macrophages dictate the progression and manifestation of hypertensive heart disease. ( 26539962 )
2015
33
Identification of molecular markers in patients with hypertensive heart disease accompanied with coronary artery disease. ( 25729940 )
2015
34
Myostatin and insulin-like growth factor-1 in hypertensive heart disease: a prospective study in human heart donors. ( 25915890 )
2015
35
Long-term physiological T3 supplementation in hypertensive heart disease in rats. ( 26254335 )
2015
36
Galectin-3 and Hypertensive Heart Disease. ( 26693838 )
2015
37
The importance of left ventricular geometry in hypertensive heart disease. ( 25915870 )
2015
38
Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. ( 25577446 )
2015
39
Comparison of right ventricular contractile abnormalities in hypertrophic cardiomyopathy versus hypertensive heart disease using two dimensional strain imaging: a cross-sectional study. ( 26245470 )
2015
40
Blood pressure control and perceived health status in African Americans with subclinical hypertensive heart disease. ( 24726098 )
2014
41
Identifying early changes in myocardial microstructure in hypertensive heart disease. ( 24831515 )
2014
42
Hypertension and hypertensive heart disease in African women. ( 24468894 )
2014
43
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease. ( 25232755 )
2014
44
Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. ( 25052897 )
2014
45
Hypertensive heart disease and obesity: a complex interaction between hemodynamic and not hemodynamic factors. ( 24821373 )
2014
46
Aldosterone and volume management in hypertensive heart disease. ( 25016402 )
2014
47
Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease. ( 25199979 )
2014
48
Left Ventricular Strain and Transmural Distribution of Structural Remodeling in Hypertensive Heart Disease. ( 24396022 )
2014
49
Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates Angiotensin II-induced hypertensive heart disease in rats. ( 24962324 )
2014
50
The role of imaging in hypertensive heart disease. ( 25075160 )
2014

Variations for Hypertensive Heart Disease

Expression for Hypertensive Heart Disease

Search GEO for disease gene expression data for Hypertensive Heart Disease.

Pathways for Hypertensive Heart Disease

Pathways related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1 12.39 AGTR1 MMP1 MMP2 MMP9
2 11.94 MMP1 MMP2 MMP9
3
Show member pathways
11.91 AGT CTF1 NPPB
4
Show member pathways
11.65 MMP1 MMP2 MMP9
5 11.51 CD36 MMP1 MMP2 MMP9
6 11.5 MMP1 MMP2 MMP9
7 11.42 ACE AGT AGTR1
8
Show member pathways
11.38 MMP1 MMP2 MMP9
9 11.33 MMP1 MMP2 MMP9
10 11.03 MMP1 MMP2 MMP9
11 10.98 MMP2 MMP9
12 10.96 AGT CTF1
13
Show member pathways
10.92 ACE AGT AGTR1 CYP11B2 NR3C2
14 10.85 MMP1 MMP2
15 10.85 ACE MMP2 MMP9
16 10.8 ACE CD36 MMP2 MMP9
17 10.74 MMP1 MMP9

GO Terms for Hypertensive Heart Disease

Cellular components related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ACE AGT CTF1 MMP1 MMP2 MMP9
2 extracellular space GO:0005615 9.17 ACE AGT CD36 CTF1 MMP2 MMP9

Biological processes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.85 AGT CD36 CTF1 NPPB
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.79 AGT AGTR1 CD36
3 kidney development GO:0001822 9.75 ACE AGT AGTR1
4 extracellular matrix disassembly GO:0022617 9.73 MMP1 MMP2 MMP9
5 regulation of blood pressure GO:0008217 9.71 ACE AGT NPPB
6 collagen catabolic process GO:0030574 9.7 MMP1 MMP2 MMP9
7 blood vessel remodeling GO:0001974 9.64 ACE AGT
8 positive regulation of protein tyrosine kinase activity GO:0061098 9.64 ACE AGT
9 endodermal cell differentiation GO:0035987 9.63 MMP2 MMP9
10 positive regulation of epidermal growth factor receptor signaling pathway GO:0045742 9.63 AGT MMP9
11 nitric oxide mediated signal transduction GO:0007263 9.62 AGT CD36
12 regulation of blood vessel size GO:0050880 9.61 AGT NPPB
13 positive regulation of cellular protein metabolic process GO:0032270 9.61 AGT AGTR1
14 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 AGT AGTR1 CD36
15 low-density lipoprotein particle remodeling GO:0034374 9.6 AGT AGTR1
16 positive regulation of renal sodium excretion GO:0035815 9.59 AGT NPPB
17 angiotensin maturation GO:0002003 9.58 ACE AGT
18 positive regulation of cholesterol esterification GO:0010873 9.57 AGT AGTR1
19 regulation of vasoconstriction GO:0019229 9.54 ACE AGT AGTR1
20 positive regulation of NAD(P)H oxidase activity GO:0033864 9.51 AGT AGTR1
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.5 AGT MMP2 MMP9
22 renin-angiotensin regulation of aldosterone production GO:0002018 9.49 AGT AGTR1
23 regulation of renal sodium excretion GO:0035813 9.48 AGT AGTR1
24 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.46 AGT AGTR1
25 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.43 AGT AGTR1 CD36
26 regulation of renal output by angiotensin GO:0002019 9.4 ACE AGT
27 regulation of vasodilation GO:0042312 9.33 ACE AGTR1 NPPB
28 regulation of blood vessel diameter GO:0097746 9.13 ACE AGTR1 NPPB
29 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.8 ACE AGT AGTR1

Molecular functions related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.77 ACE MMP1 MMP2 MMP9 NR3C2
2 peptidase activity GO:0008233 9.62 ACE MMP1 MMP2 MMP9
3 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP2 MMP9
4 endopeptidase activity GO:0004175 9.33 ACE MMP1 MMP9
5 metallopeptidase activity GO:0008237 9.26 ACE MMP1 MMP2 MMP9
6 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Hypertensive Heart Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....